Indo-National: Further investment in Medcuore Medical Solutions Pvt Ltd
Indo-National (NIPPOBATRY) filed a disclosure titled "Further investment in Medcuore Medical Solutions Pvt Ltd". The company is valued at about ₹231 crore.
What happened
Indo-National (NIPPOBATRY) filed a disclosure with the exchanges on 28 October 2026 at 12:18 PM titled "Further investment in Medcuore Medical Solutions Pvt Ltd".
From the filing: "Following this acquisition, the Company's aggregate shareholding in MMSPL now stands at 63.46%."
How big is it?
At ₹1.46 crore, the deal is equal to about 0.6% of the company's market value of ₹231 crore.
Company snapshot
Indo-National is a micro-cap company, with a market value of about ₹231 crore.
The stock last traded at ₹308, against a 52-week range of ₹257–₹469 (34.3% below the high).
Before this filing the shares had moved −7.6% over the month and −6.7% over three months. Average daily turnover over the last 20 sessions was about ₹0.04 crore.
Promoters held 65.35% at the end of Q1 FY27. Foreign institutions owned 0.00% and domestic institutions 0.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 119 | 1 | 1.37 |
| Q2 FY26 | 239 | 2.4 | 3.21 |
| Q3 FY26 | 106 | -7.8 | -10.46 |
| Q4 FY26 | 107 | -20.9 | -27.87 |
| Q1 FY27 | 116 | 2.1 | 2.85 |
What history shows
This is not the company's first m&a disclosure: BCEIE has 10 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 0.2% on average the next trading day and was down 0.5% on average after five days (10 filings with price data).
Market-wide, 2,167 m&a filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 7 Oct 2026 | Investment in Axial Aero Pvt Ltd | −1.3% | — |
| 5 Oct 2026 | M&A | −0.8% | — |
| 5 Oct 2026 | Further Investment in Medcuore Medical Solutions Pvt Ltd | −0.8% | — |
| 17 Sept 2026 | M&A | +0.9% | +1.6% |
| 11 Sept 2026 | M&A | +1.8% | +2.4% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.